BIOPORTO A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.846 DKK | +3.13% |
|
+13.39% | -11.67% |
| May. 08 | BioPorto A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 08 | Bioporto A/S Provides Earnings Guidance for 2024 | CI |
Presentation Operator MessageOperator (Operator)Welcome to this analyst call for the Interim R...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
2024-08-14
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.846
DKK
Average target price
5
DKK
Spread / Average Target
+170.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.67% | 99.01M | |
| -4.57% | 12.32B | |
| -4.35% | 8.1B | |
| +8.91% | 5.87B | |
| +30.81% | 5.52B | |
| -7.42% | 4.29B | |
| -54.27% | 3.16B | |
| +14.44% | 2.72B | |
| -2.21% | 2.37B | |
| +28.53% | 2.23B |
- Stock Market
- Equities
- BIOPOR Stock
- News BioPorto A/S
- Transcript : BioPorto A/S, Q1 2022 Earnings Call, May 11, 2022